Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Oct 1;30(10):941-946.
doi: 10.1097/IJG.0000000000001916.

Intraocular Pressure Monitoring Using an Intraocular Sensor Before and After Glaucoma Surgery

Edward Saxby  1 , Kaweh Mansouri  2   3 , Andrew J Tatham  1
Affiliations
Case Reports

Intraocular Pressure Monitoring Using an Intraocular Sensor Before and After Glaucoma Surgery

Edward Saxby et al. J Glaucoma. .

Abstract

Purpose: Intraocular pressure (IOP) is the only modifiable risk factor for glaucoma, with evidence from landmark randomized controlled trials demonstrating visual field preservation with IOP reduction. Over recent years, the use of remote sensors has formed an increasingly important component of the management of chronic diseases. During the coronavirus disease 2019 pandemic, the ability to remotely monitor IOP proved particularly useful when public stay at home orders have been in place.

Patients and methods: This report describes the first case of glaucoma surgery in a patient who had previously received an EYEMATE-IO implant. The EYEMATE-IO is an implant for IOP monitoring placed in the ciliary sulcus during cataract surgery.

Results: Remote IOP monitoring enabled the clinician to identify sustained high IOP readings and the need for glaucoma surgery. Postoperatively, response to treatment could be monitored to ensure sufficient long-term IOP control.

Conclusion: The EYEMATE-IO implanted during cataract surgery in this patient provided valuable remote continuous IOP information that guided timely glaucoma surgical interventions for poorly controlled IOP.

PubMed Disclaimer

Conflict of interest statement

Disclosure: A.J.T.: is a consultant for Allergan, Santen, and Thea; receives honoraria from Allergan, Heidelberg Engineering, Santen, Glaukos, and Novartis; receives grant support from Allergan and Novartis. K.M.: is a consultant for Implandata; receives honoraria from Santen, Thea, and Allergan. E.S. declares no conflict of interest.

References

    1. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295–1304.
    1. Leske MC, Heijl A, Hyman L, et al. EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–1972.
    1. Aptel F, Weinreb RN, Chiquet C, et al. 24-h monitoring devices and nyctohemeral rhythms of intraocular pressure. Prog Retin Eye Res. 2016;55:108–148.
    1. Rotchford AP, King AJ. Repeatability of measurements of effectiveness of glaucoma medication. Br J Ophthalmol. 2012;96:1494–1497.
    1. Beck D, Tatham AJ. Self-monitoring of intraocular pressure in glaucoma. Expert Rev Ophthalmol. 2019;14:219–225.

Publication types